Jubilant Life Sciences (Jubilant), through one of its units Jubilant DraxImage, Canada, has received USFDA 505 (b)(2) approval (new drug application) for Ruby-fill (Rubidium 82). Ruby-fill is used for nuclear cardiology diagnostic positron emission tomography (PET) procedure to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease. The product is expected to be launched in Q3FY17. As per management estimates, the current US market size is US$76 mn and has potential to grow up to US$250 million annually in the...